• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of epigenetic treatment on SST expression in neuroendocrine tumour patients.

作者信息

Refardt Julie, Klomp Maria J, van Koetsveld Peter M, Dogan Fadime, Konijnenberg Mark, Brabander Tessa, Feelders Richard A, de Herder Wouter W, Hofland Leo J, Hofland Johannes

机构信息

ENETS Center of Excellence, Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands.

ENETS Center of Excellence, Department of Endocrinology, University Hospital Basel, Basel, Switzerland.

出版信息

Clin Transl Med. 2022 Jul;12(7):e957. doi: 10.1002/ctm2.957.

DOI:10.1002/ctm2.957
PMID:35866246
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9304941/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4344/9304941/44381eb1406b/CTM2-12-e957-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4344/9304941/d9ecdb7c2fee/CTM2-12-e957-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4344/9304941/44381eb1406b/CTM2-12-e957-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4344/9304941/d9ecdb7c2fee/CTM2-12-e957-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4344/9304941/44381eb1406b/CTM2-12-e957-g001.jpg

相似文献

1
Effect of epigenetic treatment on SST expression in neuroendocrine tumour patients.表观遗传治疗对神经内分泌肿瘤患者SST表达的影响。
Clin Transl Med. 2022 Jul;12(7):e957. doi: 10.1002/ctm2.957.
2
Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.神经内分泌肿瘤——生长抑素受体表达与生长抑素类似物治疗
Cancer Chemother Biol Response Modif. 2003;21:535-46.
3
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.帕西瑞肽和奥曲肽对人胰腺神经内分泌肿瘤培养物的抗增殖作用及SST2转运
Endocr Relat Cancer. 2014 Oct;21(5):691-704. doi: 10.1530/ERC-14-0086. Epub 2014 Jul 10.
4
Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy.地西他滨对神经内分泌肿瘤中生长抑素-2的表观遗传增强作用，作为一种允许进行肽受体放射治疗的新方法。
Eur J Cancer. 2022 Nov;176:110-120. doi: 10.1016/j.ejca.2022.09.009. Epub 2022 Oct 5.
5
Carboxyl-terminal multi-site phosphorylation regulates internalization and desensitization of the human sst2 somatostatin receptor.羧基末端多位点磷酸化调节人类生长抑素2型受体的内化和脱敏。
Mol Cell Endocrinol. 2014 Apr 25;387(1-2):44-51. doi: 10.1016/j.mce.2014.02.009. Epub 2014 Feb 22.
6
Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.胃肠胰神经内分泌肿瘤中的生长抑素受体
Endocr Relat Cancer. 2003 Dec;10(4):451-8. doi: 10.1677/erc.0.0100451.
7
Drug Development in Neuroendocrine Tumors: What Is on the Horizon?神经内分泌肿瘤的药物研发：前景如何？
Curr Treat Options Oncol. 2021 Mar 30;22(5):43. doi: 10.1007/s11864-021-00834-3.
8
Clinical relevance of somatostatin receptor imaging.生长抑素受体显像的临床相关性。
Eur J Endocrinol. 1994 Dec;131(6):575-6. doi: 10.1530/eje.0.1310575.
9
111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours.神经内分泌肿瘤中生长抑素受体亚型2对111铟标记的奥曲肽的结合
Br J Surg. 2003 May;90(5):549-54. doi: 10.1002/bjs.4069.
10
The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors.SST2 转运和信号转导在胰腺神经内分泌肿瘤治疗中的作用。
Mol Cell Endocrinol. 2021 May 1;527:111226. doi: 10.1016/j.mce.2021.111226. Epub 2021 Mar 3.

引用本文的文献

1
Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.提高神经内分泌肿瘤对放射性核素治疗的敏感性：互补治疗的个性化方法。
Theranostics. 2024 Jan 1;14(1):17-32. doi: 10.7150/thno.87345. eCollection 2024.
2
The role of DNA methylation in human pancreatic neuroendocrine tumours.DNA甲基化在人类胰腺神经内分泌肿瘤中的作用。
Endocr Oncol. 2023 Apr 17;3(1):e230003. doi: 10.1530/EO-23-0003. eCollection 2023 Jan 1.
3
Epigenetic regulation of SST expression in small intestinal neuroendocrine tumors.

本文引用的文献

1
Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [In]In-DOTATATE Uptake in NET Cells.比较多种组蛋白去乙酰化酶抑制剂对神经内分泌肿瘤细胞中生长抑素受体2（SSTR2）表达及[铟-111]依替膦酸（[In]In-DOTATATE）摄取的影响。
Cancers (Basel). 2021 Sep 29;13(19):4905. doi: 10.3390/cancers13194905.
2
Potential for Increasing Uptake of Radiolabeled Ga-DOTATOC and I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.使用组蛋白去乙酰化酶抑制剂伏立诺他增加中肠神经内分泌肿瘤患者放射性标记 Ga-DOTATOC 和 I-MIBG 的摄取的潜力。
Cancer Biother Radiopharm. 2021 Oct;36(8):632-641. doi: 10.1089/cbr.2020.4633. Epub 2021 Jul 12.
3
小肠神经内分泌肿瘤中 SST 表达的表观遗传调控。
Front Endocrinol (Lausanne). 2023 May 8;14:1184436. doi: 10.3389/fendo.2023.1184436. eCollection 2023.
4
Up-Regulation of PSMA Expression In Vitro as Potential Application in Prostate Cancer Therapy.前列腺特异性膜抗原（PSMA）体外表达上调在前列腺癌治疗中的潜在应用
Pharmaceuticals (Basel). 2023 Apr 4;16(4):538. doi: 10.3390/ph16040538.
5
Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models.在生长抑素 2 型受体放射性核素治疗学和小鼠嗜铬细胞瘤模型中的辐射转录组学中应用表观遗传药物。
Theranostics. 2023 Jan 1;13(1):278-294. doi: 10.7150/thno.77918. eCollection 2023.
6
Peptide Receptor Radionuclide Therapy.肽受体放射性核素治疗。
J Clin Endocrinol Metab. 2022 Nov 25;107(12):3199-3208. doi: 10.1210/clinem/dgac574.
Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours.
使用 [Lu]Lu-DOTA-TATE 克服肽受体放射性核素治疗中的肾毒性，用于治疗神经内分泌肿瘤。
Nucl Med Biol. 2021 Nov-Dec;102-103:1-11. doi: 10.1016/j.nucmedbio.2021.06.006. Epub 2021 Jul 1.
4
Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging.生长抑素受体显像阴性的神经内分泌肿瘤患者的预后较差。
Endocr Relat Cancer. 2020 Nov;27(11):615-624. doi: 10.1530/ERC-20-0340.
5
Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells.表皮生长因子诱导人胰腺神经内分泌肿瘤细胞中功能性生长抑素2型受体上调。
Oncotarget. 2016 May 19;9(19):14791-14802. doi: 10.18632/oncotarget.9462. eCollection 2018 Mar 13.
6
Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).使用肼屈嗪/丙戊酸盐（TRANSKRIP™）作为骨髓增生异常综合征（MDS）的表观遗传治疗的同情用药取得了令人鼓舞的结果。
Ann Hematol. 2017 Nov;96(11):1825-1832. doi: 10.1007/s00277-017-3103-x. Epub 2017 Aug 23.
7
Upregulation of Key Molecules for Targeted Imaging and Therapy.上调靶向成像和治疗的关键分子。
J Nucl Med. 2016 Nov;57(11):1805-1810. doi: 10.2967/jnumed.115.165092. Epub 2016 Jun 30.
8
Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.肼屈嗪-丙戊酸盐：一种用于癌症表观遗传治疗的重新定位的药物组合。
Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1433-44. doi: 10.1517/17425255.2014.947263. Epub 2014 Aug 25.
9
Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.镓 68 DOTATOC 正电子发射断层扫描成像在神经内分泌肿瘤中的可重复性。
Pancreas. 2013 Aug;42(6):937-43. doi: 10.1097/MPA.0b013e318287ce21.
10
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes.一项关于肼屈嗪使肿瘤抑制基因去甲基化并重新激活其表达的I期研究。
BMC Cancer. 2005 Apr 29;5:44. doi: 10.1186/1471-2407-5-44.